This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Aortic arch syndrome [Takayasu]대동맥궁증후군 [다카야수] (대동맥궁증후군)

Contents and key points
ItemDetails
A. Classification codesICD-10: M31.4 (aortic arch syndrome [Takayasu]) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsTakayasu arteritis, pulseless disease, Takayasu arteritis, TAK, Pulseless disease, Nonspecific aortoarteritis
C. Adult onsetOccurs mainly in women under 40; diagnostic delay is common, so it is often first confirmed in adulthood.
1. HistoryIn 1908 Mikito Takayasu reported wreath-like retinal vascular anastomoses; later systematized as nonspecific aortoarteritis
2. CausesAutoimmune-mediated granulomatous vasculitis of large vessels; T cell and NK cell activation, autoantigen unknown
3. GeneticsHLA-B*52:01 major susceptibility allele; non-HLA loci IL12B, FCGR2A/3A, IL6, RPS9/LILRB3
4. General epidemiologyHighest prevalence in Japan at 40/million; concentrated in Asia, the Middle East and Latin America; female:male ≈ 8–9:1
5. PathophysiologyDendritic cell activation → recruitment of Th1/Th17 → granulomatous panarteritis progressing from the adventitia to the intima
6. SymptomsEarly: fever, fatigue, arthralgia; late: pulse loss, upper limb claudication, hypertension, cerebral ischemia, visual disturbance
7. SignsLoss of upper limb pulses, vascular bruits, blood pressure differences, carotid tenderness, retinopathy, hypertension
8. ScreeningESR, CRP, IL-6, vascular ultrasound, ABI (ankle-brachial index), lower limb blood pressure measurement
9. Diagnosis2022 ACR/EULAR classification criteria, CT/MR angiography, FDG-PET, angiography
10. TreatmentGlucocorticoids as first-line treatment, combined with methotrexate or azathioprine; tocilizumab and TNF inhibitors as second-line treatment
11. Prognosis5-year survival 80–90%; frequent relapses; vascular stenosis, aneurysms and hypertensive complications are the main causes of long-term morbidity
12. PreventionPrevention of vascular complications through early diagnosis, aggressive immunosuppression, blood pressure control and regular imaging follow-up
13. References2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis … and 9 other papers

1. History

Takayasu arteritis (TAK) first appeared in the scientific literature in 1908, when the Japanese ophthalmologist Mikito Takayasu (Goanuin) reported a 21-year-old woman with wreath-shaped arteriovenous anastomoses in the retina and cataracts. At the same meeting that year, Onishi and Kato observed loss of the radial pulse in similar patients, and as these two findings were combined, the disease acquired the nickname "pulseless disease." Later, in the 1940s, Oshima et al. confirmed by angiography that the disease is a systemic vasculitis involving the aorta and its main branches.

In 1951 Shimizu and Sano systematized the features of the disease as pulse loss, ocular complications and carotid hypersensitivity, introducing the name "Takayasu's disease" internationally. In the 1960s–70s similar cases were reported one after another from many countries, including India, China, Mexico and Brazil, and it was recognized that the disease is not confined to Asia but has a worldwide distribution. Accordingly, the disease also came to be called "nonspecific aortoarteritis."

In 1990 the American College of Rheumatology (ACR) published 6-item classification criteria, which served as the standard for research and clinical practice for some 30 years. In 2022, revised ACR/EULAR classification criteria based on a large international cohort were published, addressing the limitations of the previous criteria. As results of clinical trials of biologics in Takayasu arteritis, particularly the IL-6 receptor blocker tocilizumab, were published from 2018 onward, the treatment paradigm changed considerably. Today, data on patient phenotypes, genetic factors and treatment outcomes continue to accumulate through global rare vasculitis registry studies (such as DCVAS).


2. Causes

The exact cause of Takayasu arteritis has not yet been fully elucidated, but it is understood that in genetically susceptible individuals, environmental or infectious triggers initiate an abnormal autoimmune response. The core feature of the disease is a chronic granulomatous vasculitis involving the full thickness of the aorta and its main branches, in which activated CD4+ and CD8+ T cells, NK cells and macrophages infiltrate the vessel wall, causing intimal thickening, stenosis, occlusion or aneurysm.

Aortic endothelial cell antigens (antiaortic antibody) and HSP65 (heat shock protein 65) have been proposed as autoantigens. Several studies have raised the hypothesis that Mycobacterium tuberculosis infection may act as a trigger of the immune response; indeed, Takayasu arteritis is more frequent in regions with high tuberculosis prevalence, and there are reports of symptom improvement in some patients after antituberculosis treatment. However, this association has not been established as causal.

Immunologically, the Th1 and Th17 pathways have been identified as the main inflammatory circuits. IFN-γ secreted by Th1 cells activates macrophages and contributes to granuloma formation, and IL-17 secreted by Th17 cells promotes angiogenesis and fibrosis in the vessel wall. Proinflammatory cytokines such as IL-6, TNF-α and IL-12 are directly involved in disease activity and progression of vascular lesions, and the therapeutic effect of biologics targeting these cytokines has been confirmed clinically.


3. Genetics

The best-established factor in genetic susceptibility to Takayasu arteritis is the HLA-B*52:01 allele. This allele is consistently associated with high risk (OR 1.9–3.5) in Japanese, Korean and Indian cohorts, and in HLA-B52-positive patients HLA-B*52:01 is presumed to cause aortic endothelial cell injury through cytotoxic T lymphocyte (CTL) responses. HLA-B*40:01 has also been identified as an independent risk factor in Japanese studies.

Genome-wide association studies (GWAS) have also identified many non-HLA susceptibility loci. In particular, variants in the IL12B gene (encoding the IL-12 p40 subunit) are the non-HLA genetic factor most strongly associated with the development of Takayasu arteritis and are understood to amplify vascular inflammation by promoting Th1 and Th17 differentiation through the IL-12/IL-23 axis. In addition, FCGR2A/FCGR3A (Fc-gamma receptors), IL6, RPS9/LILRB3 and a locus near PSMG1 on chromosome 21 have shown significant associations in GWAS.

Korean cohort studies have confirmed the HLA-B52 association and, as a non-HLA factor, reported an association with the MLX (MAX-like protein X) gene region. Takayasu arteritis mostly occurs sporadically and familial clustering is rare, but discordant cases in identical twins also suggest a role for environmental factors. From the perspective of gene-environment interaction, the hypothesis that the combination of IL-12B variants and a history of tuberculosis infection raises the risk of disease is being studied.


4. General epidemiology

Takayasu arteritis is distributed worldwide but shows markedly higher incidence in Asia, the Middle East and Latin America. Japan's prevalence of about 40 per 100,000 is the highest in the world, and relatively high incidence is also reported in Korea and China. Incidence in Western countries is low, at about 1–3 per million.

The sex distribution shows overwhelming female predominance, with a female-to-male ratio of roughly 8–9:1. Age at onset is mainly 10–40 years, and onset after 40 is rare. The median age at onset is reported to be about 25–30 years. In Korea, analysis of health insurance claims data has shown the highest frequency of diagnosis in women in their 20s–40s, and it accounts for a considerable share of the vasculitis category among patients registered for Special Copayment Reduction for rare diseases.

Ethnic differences are also reflected in clinical phenotypes: in Asians, involvement of the aortic arch and intracranial vessels is common, whereas in Indians involvement of the abdominal aorta and renal arteries is relatively more frequent, so renovascular hypertension complications are common. Worldwide, the annual incidence of new cases is about 1–2 per million, making it a rare disease. With appropriate treatment the 5-year survival rate is 80–90%, but without treatment survival is markedly shortened by ischemic stroke, myocardial infarction, kidney failure and other causes.


5. Pathophysiology

The pathogenesis of Takayasu arteritis is explained by the coordinated activation of innate and adaptive immunity. The earliest stage begins with activation of vascular dendritic cells located in the aortic adventitia. These dendritic cells present autoantigens not yet fully identified or infectious triggers (molecular mimicry by Mycobacterium tuberculosis, etc.), driving naive CD4+ T cells to differentiate into the Th1 and Th17 lineages.

Activated Th1 cells secrete IFN-γ and TNF-α, recruiting and activating macrophages and multinucleated giant cells in the vessel wall and forming granulomatous inflammatory foci. Th17 cells amplify the inflammatory response of vascular smooth muscle cells and endothelial cells through IL-17 and IL-22 and promote vascular remodeling. CD8+ cytotoxic T cells and NK cells also infiltrate along the internal elastic lamina and contribute to direct injury of endothelial and smooth muscle cells via the perforin/granzyme pathway.

IL-6 acts as a key mediator throughout this process, and serum IL-6 levels correlate significantly with disease activity. Extracellular matrix degradation by MMP-2 and MMP-9 and angiogenesis from VEGF overexpression promote intimal thickening, while conversely destruction of medial elastic fibers and loss of smooth muscle cells lead to aneurysm formation. The result is complex changes in vascular anatomy in which vascular stenosis (the typical form) and aneurysms (a rare form) coexist. The Kerr classification (type I-V) is an anatomical classification system based on the distribution of involved vessels, and each type reflects the spatial predominance of the pathogenic process.


6. Symptoms

The clinical course of Takayasu arteritis is typically divided into two phases. The prepulseless phase is dominated by nonspecific systemic symptoms, with fever, night sweats, fatigue, weight loss, arthralgia, myalgia and skin rashes (erythema nodosum, etc.) appearing over several months. Because there are no specific vascular symptoms at this stage, it is difficult to distinguish from rheumatic diseases, infections and malignancies.

In the occlusive phase, ischemic symptoms from vascular stenosis and occlusion come to the fore. Upper limb claudication (fatigue or pain when using the arms), a cold sensation and pulse loss due to reduced upper limb blood flow are characteristic. Reduced cerebral blood flow causes headache, dizziness, syncope, stroke and vision loss. Renal artery involvement causes renovascular hypertension, which must always be considered in the differential diagnosis of refractory hypertension, especially in adolescents or young adults.

Thoracoabdominal aortic involvement may cause lower limb claudication, abdominal pain and symptoms of intestinal ischemia, and with cardiac involvement, chest pain, heart failure and myocardial infarction symptoms may also be seen. Pulmonary artery involvement (rarely, in type V) can cause the symptoms of pulmonary hypertension: dyspnea, cough and hemoptysis. In patients whose vascular stenosis is already advanced at diagnosis, the systemic symptoms of the prepulseless phase have often disappeared, giving a quiet clinical course.


7. Signs

The hallmark physical sign of Takayasu arteritis is loss or reduction of upper or lower limb pulses. When pulses are palpated or blood pressure is measured simultaneously in both arms and there is a difference of 10 mmHg or more, subclavian or axillary artery stenosis is strongly suggested. Bruits over the carotid, radial and brachial arteries are also common.

On vascular auscultation, bruits over the abdominal aorta, renal arteries and iliac arteries suggest abdominal vascular involvement. Renovascular hypertension may cause unexpectedly severe hypertension at a young age, sometimes accompanied by an abdominal bruit. Eye examination may reveal retinal vascular changes (hypoxic retinopathy, wreath-like anastomoses), secondary glaucoma or anterior ischemic optic neuropathy.

Palpation of the carotid artery may reveal tenderness or a firm feel, reflecting inflammation and thickening of the vessel wall. Cardiac examination may show an aortic regurgitation murmur, a mitral regurgitation murmur and signs of left ventricular hypertrophy. On the skin, signs of vascular complications such as erythema nodosum, necrotizing vasculitis lesions and skin ulcers may appear. Atrophy, coldness and color changes of the limbs reflect chronic ischemia.


8. Screening

In patients with suspected Takayasu arteritis, the first step in screening is measurement of acute phase reactants, including ESR and CRP. ESR is frequently elevated in active disease, but about 25–30% of patients are clinically active with normal acute phase reactants, so combination with imaging is essential. Studies have found that serum IL-6 measurement is a more sensitive marker of activity than ESR/CRP.

Basic blood tests include a complete blood count (normocytic anemia, thrombocytosis), serum chemistry (renal and liver function) and urinalysis (proteinuria, hematuria), which help assess renal artery involvement. Bilateral upper limb blood pressure measurement and pulse palpation are the simplest yet most important screening tools; a systolic blood pressure difference of ≥10 mmHg between the arms suggests significant vascular stenosis. Measurement of the ankle-brachial index (ABI) is useful for screening for lower limb vascular involvement.

Vascular ultrasound (duplex ultrasonography) is a noninvasive tool that evaluates thickening of the carotid and subclavian artery walls and changes in flow velocity, and it is increasingly included as part of screening at diagnostic centers. Eye examination helps detect retinal vascular changes early, and Takayasu arteritis should be considered especially in young women complaining of unexplained vision loss.


9. Diagnosis

Takayasu arteritis is diagnosed by integrating clinical symptoms, blood tests and imaging findings, and the revised 2022 ACR/EULAR classification criteria are used as the standard for research purposes. These criteria sum points for several items, including age (≤60 years), vascular bruits, reduced upper limb pulses or upper limb claudication, upper limb blood pressure difference, imaging findings (abnormalities of the aorta or main branches) and angiographic findings; when a sufficient score is obtained, the classification criteria are met (sensitivity 87%, specificity 95%).

In imaging diagnosis, CT angiography (CTA) is the standard test for rapidly evaluating vascular stenosis, occlusion, aneurysm and wall thickening. MR angiography (MRA) can evaluate vessel wall inflammation (T2 hyperintensity) without radiation and is preferred in young female patients. FDG-PET/CT most sensitively reflects active vascular inflammation (sensitivity 70–84%) and is useful for assessing activity before treatment and monitoring treatment response.

Conventional digital subtraction angiography (DSA) defines vascular anatomy most precisely but is invasive, so it is performed mainly when an interventional procedure is planned. Tissue biopsy is not routinely performed because of the risks of accessing the aorta and main branches, but in specimens obtained during aortic surgery, granulomatous panarteritis progressing from the adventitia toward the intima, with CD4+ T cell and histiocyte infiltration, constitutes the pathological diagnostic criterion.


10. Treatment

The treatment goals for Takayasu arteritis are induction and maintenance of remission of vascular inflammation, prevention of further vascular damage and prevention of ischemic complications. Glucocorticoids are the first-line treatment: in active disease, prednisolone is started at 0.5–1 mg/kg/day (maximum 40–60 mg/day) and tapered slowly over 6–12 months. However, in more than about 50% of patients, steroids alone lead to relapse or steroid dependence, so combination with immunosuppressants is needed.

Among conventional immunosuppressants, methotrexate (MTX) is the most widely used (15–25 mg/week orally or subcutaneously), and azathioprine (AZA, 2 mg/kg/day), mycophenolate mofetil (MMF, 2–3 g/day) and leflunomide are also used. Biologics are introduced when the disease is refractory to steroids and DMARDs or relapses repeatedly. Tocilizumab (IL-6R blocker, TCZ) showed a significant effect in reducing the risk of relapse in an international open study (the TAKT study) and is recommended by EULAR, together with TNF-α inhibitors, as a second-line option. There is also evidence that TNF-α inhibitors such as infliximab and etanercept are effective for inducing and maintaining remission.

Vascular interventional treatment is performed on vascular lesions that have stabilized after remission with medical therapy, with percutaneous transluminal angioplasty (PTA) and stenting applied to stenosed vessels. Bypass surgery has excellent long-term patency and is preferred for proximal large vessel lesions. Vascular procedures during active inflammation increase the risk of restenosis and complications, so the rule is to perform them after inflammation is suppressed. Blood pressure control is essential for preventing complications, and ACE inhibitors or angiotensin receptor blockers are recommended first-line for renovascular hypertension.


11. Prognosis

With appropriate treatment, the 5-year survival rate of Takayasu arteritis reaches 80–90%, but it is a chronic disease requiring continued follow-up because relapses and complications are frequent in the long term. The relapse rate is reported to be about 50% or higher, and most patients experience relapse during glucocorticoid tapering. Repeated relapses accumulate further vascular damage, raising the risk of vascular stenosis, aneurysm and thrombus formation.

Long-term complications include renovascular hypertension (with renal artery involvement), aortic regurgitation (with aortic root involvement), ischemic stroke (with carotid involvement), myocardial infarction (with coronary ostial involvement) and vision loss (with retinal vascular complications). When an aortic aneurysm is present there is a risk of rupture, and continued imaging follow-up is needed. Because there is a risk that Takayasu arteritis will flare or hypertensive complications will worsen during pregnancy, disease stabilization before pregnancy and high-risk obstetric management are needed.

Known poor prognostic factors include diagnostic delay, extensive vascular involvement at diagnosis (type IV-V), repeated relapses, treatment refractoriness, and coexisting hypertension and cardiovascular risk factors. Because structural abnormalities of the vessel wall may persist even during remission, regular imaging monitoring with PET-CT and MRA is central to long-term management.


12. Prevention

Primary prevention of Takayasu arteritis is not yet possible, but prompt initiation of treatment through early diagnosis is the best preventive strategy to limit the accumulation of vascular damage. In young women with unexplained hypertension, pulse differences or vascular bruits, this disease must be included in the differential diagnosis, and early diagnosis significantly reduces vascular complications and organ damage.

There is a hypothesis that prevention and treatment of tuberculosis may potentially suppress triggering of this disease, and in regions at high risk of tuberculosis, active tuberculosis prevention policies may have an indirect preventive effect. In confirmed patients, isoniazid prophylaxis should be considered to prevent steroid-induced infection. Because smoking can further impair vascular endothelial function and worsen vascular inflammation, strict smoking cessation is recommended.

Management of cardiovascular risk factors (hypertension, hyperlipidemia, diabetes) is central to secondary prevention of vascular complications. With long-term high-dose steroid use, calcium and vitamin D supplementation, bone density monitoring and gastrointestinal protective agents should be used together to prevent adverse effects such as osteoporosis, diabetes and infection. Even after active inflammation is controlled, ESR/CRP measurement every six months and vascular imaging follow-up once or twice a year are needed for early detection of relapse and vascular complications.


13. References

  1. Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis. Arthritis & Rheumatology. 2022;74(12):1872–1880. DOI: 10.1002/art.42324. PMID: 36349478.

  2. Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu arteritis observed at a cross-sectional nationwide survey in Japan. Circulation. 2015;132(18):1701–1709. DOI: 10.1161/CIRCULATIONAHA.114.012257. PMID: 26362640.

  3. Saruhan-Direskeneli G, Hughes T, Aksu K, et al. Identification of multiple genetic susceptibility loci in Takayasu arteritis. American Journal of Human Genetics. 2013;93(2):298–305. DOI: 10.1016/j.ajhg.2013.05.026. PMID: 23830517.

  4. Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis & Rheumatism. 2004;50(7):2296–2304. DOI: 10.1002/art.20300. PMID: 15248230.

  5. Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Annals of the Rheumatic Diseases. 2018;77(3):348–354. DOI: 10.1136/annrheumdis-2017-211878. PMID: 29146650.

  6. Tombetti E, Mason JC. Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology (Oxford). 2019;58(2):206–219. DOI: 10.1093/rheumatology/key040. PMID: 29648650.

  7. Misra R, Danda D, Rajappa SM, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). 2013;52(10):1795–1801. DOI: 10.1093/rheumatology/ket125. PMID: 23592762.

  8. Alibaz-Oner F, Direskeneli H. Advances in Takayasu arteritis: an Asia Pacific perspective. Frontiers in Medicine. 2022;9:952972. DOI: 10.3389/fmed.2022.952972. PMID: 36035434.

  9. Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford). 2014;53(5):793–801. DOI: 10.1093/rheumatology/ket430. PMID: 24388977.

  10. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases. 2020;79(1):19–30. DOI: 10.1136/annrheumdis-2019-215672. PMID: 31270110.